RQC to prevent Alzheimer's and eye changes
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests an oral medication called RQC to see if it can help prevent Alzheimer's disease and related eye changes. It is for adults aged 50–90 who do not have major memory problems or other serious health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 90 years old.
- You do not have any major memory or thinking problems that affect your daily life.
- You have never taken Leqembi or Aduhelm (Alzheimer's antibody treatments).
- You do not have a serious stomach condition, such as IBS, Crohn's disease, or ulcers.
- You do not have kidney or liver disease.
- You can take oral medication and come to study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication, CORT108297, that may help protect the brain from the harmful effects of stress in people at risk for Alzheimer's disease. It is looking for adults age 55 and older who either have mild memory problems or are healthy but have a family history, APOE4 gene, or memory concerns.
This trial tests whether a natural plant compound can help support memory and thinking in people at higher risk for Alzheimer's disease. You may qualify if you are over 50, overweight, eat a typical Western diet, and have a family history of Alzheimer's.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This trial tests an investigational drug called AMDX-2011P for people with Alzheimer's disease. It looks at whether the drug affects the retina, which may be linked to brain changes in Alzheimer's.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study looks at how well people with Alzheimer’s disease (AD) or mild cognitive impairment (MCI) perform on standardized memory/brain tests. It may help researchers understand changes over time, and whether certain types of brain signals or test results track with the condition.
Hear when a new Mild Cognitive Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.